Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $5.8 million.

  • Viking Therapeutics' Change in Accured Expenses fell 142.57% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 million, marking a year-over-year decrease of 121.25%. This contributed to the annual value of $5.8 million for FY2024, which is 420.26% up from last year.
  • As of FY2024, Viking Therapeutics' Change in Accured Expenses stood at $5.8 million, which was up 420.26% from -$1.8 million recorded in FY2023.
  • Viking Therapeutics' 5-year Change in Accured Expenses high stood at $5.8 million for FY2024, and its period low was -$1.8 million during FY2023.
  • For the 3-year period, Viking Therapeutics' Change in Accured Expenses averaged around $3.3 million, with its median value being $5.8 million (2022).
  • In the last 5 years, Viking Therapeutics' Change in Accured Expenses surged by 1,248.02% in 2022 and then crashed by 131.26% in 2023.
  • Viking Therapeutics' Change in Accured Expenses (Yearly) stood at $3.8 million in 2020, then crashed by 113.43% to -$506,000 in 2021, then skyrocketed by 1,248.02% to $5.8 million in 2022, then tumbled by 131.26% to -$1.8 million in 2023, then soared by 420.26% to $5.8 million in 2024.